INTRODUCTION
For decades, the development of medical nanotechnology, now a cornerstone of modern medicine, has allowed innovative applications [1] . In oncology, Doxil TM and Abraxame TM are two representative nanoparticle formulations, which contain doxorubicin and taxol, respectively, and are used to treat cancer. In general, the use of nanoparticles results in a decrease in toxicity and an increase in efficacy compared with the drug alone [2, 3] . In medicine, nanoparticles have been described using several different types, including liposomes, albumin-based particles, biodegradable polymer-drug composites, PEGylated proteins, polymeric micelles, polymer-drug conjugate-based particles, carbon nanomaterials, inorganic particles, dendrons, and dendrimers [4] . Developed in the last 30 years, dendrimers represent an important versatile and well-defined nanosized architecture. Dendrimers have played a key role in drug delivery with several advantages: 1) reducing the toxicity of the drug alone; 2) extending the route of administration; 3) improving the disease outcomes of drugs; and 4) improving the pharmacokinetic/pharmacodynamic (PK/PD) profile of drugs. Drug delivery systems and dendrimers as drugs alone are the two main therapeutic applications of dendrimers. Dendrimers exhibit a number of important attributes in nanomedicine, including homogeneity, monodispersity derivatisability, reproducibility, tailored multivalency, higher permeation and circulation, and strong spatial distribution of multiple functions on their surface, which are important for the delivery of active pharmaceutical agents, such as small and macrocyclic drugs, small interfering RNAs, and antibodies, for several pharmaceutical applications, including cancer, inflammation, and infection (e.g., HIV).
Several types of dendrimers have been highlighted, and can be classified based on their chemical moieties and the type of structural linkages: glycodendrimers, peptide dendrimers, Janus dendrimers, metallodendrimers, and phosphorus dendrimers [5] [6] [7] . Dendrimers can be compared with proteins based on their size and physicochemical properties. Biodegradability and biocompatibility are important for the bioapplications of dendrimers, especially blood circulation and possible side effects, respectively, in vivo.
In 2012, Starpharma initiated two pivotal Phase III trials for the treatment of bacterial vaginosis with VivaGel® (SPL7013 Gel) [8, 9] . This active polyanionic G4-poly (L-lysine)-type dendrimer has 32 naphthalene disulphonate groups on the surface, and showed potent topical vaginal microbicidal activity. Starpharma has now received Food and Drug Administration Phase III approval. Starpharma/AstraZeneca has recently advanced from Phase I to Phase II with a poly(lysine)-dendrimer based nanocarrier encapsulating docetaxel (DEP® docetaxel), which shows superior anticancer activity against several solid cancer types, including breast, prostate, lung, and ovarian tumors.
Theranostics is an emerging noninvasive concept that enables the simultaneous use of diagnostic tests and targeted therapy. This strategy is based on multifunctional nanoparticles as one integrated system (a single platform), and simultaneous monitoring of the therapeutic response. Over the past few decades, theranostic nanoparticles (TNPs) that simultaneously transmit diagnostic information and monitor the therapy process in situ have been developed [10, 11] . The objective of diagnostic agents is to enhance the visibility of specific tissues, providing a quick and high fidelity snapshot of the living system with a rapid and slow clearing strategy, whereas therapeutic agents generally play their specific treatment role with the long-circulating profile of nanoparticles.
The typical imaging modalities are: 1) optical imaging using photons from bioluminescent or fluorescent probes; 2) magnetic resonance imaging (MRI) using gadolinium (Gd) [12] , and manganese oxide based on the precession of water hydrogen nuclei within an applied magnetic field; 3) radionuclide-based imaging using the electromagnetic spectrum γ-ray emissions (positron emission tomography (PET) and single photon computed tomography (SPECT)); 4) computed tomography (CT) measuring the absorption of X-rays through tissues, with gold nanoparticles as the most popular CT contrast agent; and 5) ultrasound (US), high frequency sound waves >20 kHz. Table 1 shows the main imaging modalities as well as the advantages and disadvantages of the molecular imaging strategies for theranostic applications.
The main effective TNPs are 1) drug conjugates (e.g., N-(2-hydroxypropyl)methacrylamide (HPMA) and complexes; 2) vesicles such as liposomes and polymer vesicles; 3) micelles (e.g., polyethylene glycol-polylactic acid (PEG-PLA); 4) core-shell structured TNPs including quantum dots (QDs), metals, and metal oxides; 5) microbubbles (e.g., PEG-poly-L-lactide/perfluoropentane (PEG-PLLA/ PFP); 6) carbon nanotubes; and 7) polymeric materials such as aliphatic polyesters [13] , dendritic polymers [11] , and dendrimers (e.g., polyamidoamine dendrimer-PEG (PAMAM-PEG)) [14] .
TNPs, except dendrimers, are primarily developed for use in cancer treatment (Table 2) . Indeed, conventional chemotherapy shows a low therapeutic window and poor prognosis of patients diagnosed with metastatic cancers. Consequently, the development of newer strategies to simultaneously detect cancer lesions at an early stage and to precisely deliver anticancer drugs to tumor sites remains an important area of research.
Dendrimers are hyperbranched nanostructures with controlled functionality and are vehicles that can be efficiently tailored for the spatial distribution of various functionalities on their surface. These versatile functions, which allow stimuli-response ability and the ability to self-assembly, make dendrimers excellent candidates for theranostic applications [5] . Importantly, the co-delivery of diagnostic and therapeutic agents represents a valuable real-time validation of therapy. Fig. 1 shows a schematic illustration of a theranostic dendrimer for simultaneous diagnosis, therapy, and therapeutic monitoring.
Cancer theranostics has been developed to fight this terrible disease by improving treatment efficiency and by precisely diagnosing specific cancer types and monitoring therapy. Several imaging methods, such as US, CT, PET, and MRI, have been developed for this purpose. However, none of these imaging techniques represent ivory towers. Several limitations have been noted, including poor resolution, inherent radiation damage, and high equipment costs. In comparison with these methods, conventional fluorescence imaging techniques exhibit advantages: high spatial resolution, strong biocompatibility, and low cost. However, due to the aggregation-caused quenching effect and background noise in dilute solutions, applications of these techniques in theranostics have been strongly limited. Aggregation-induced emission probes show excellent photo-stability and a reduced self-quenching effect and have been incorporated into theranostic platforms. Up until now, no ideal TNPs have been developed and theranostics remains an important area of research in nanomedicine to treat important chronic diseases such as cancer.
In this concise review, we briefly summarize and describe the recent progress in the development of dendrimers for theranostic applications in oncology. In particular, we analyze their specific properties in relation with theranostic-related applications.
DENDRIMERS FOR THERANOSTIC APPLICATIONS
Based on the precise regulation of the polymerization and synthesis of polymeric dendrimers, the molecular weight and chemical composition (polydispersity) of the final Passive diffusion [21] a: N-(2-hydroxypropyl)methacrylamide, b: poly(lactic-co-glycolic acid), c: polylactic acid, d: poly(g-benzyl-L-glutamate)-block-hyaluronan; e: polyacrylic acid; f: superparamagnetic iron-oxide; g: pentafluorophenyl ester; h: 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate; i: epidermal growth factor; j: Arg-Gly-Asp peptide Selected examples of the design of targeted dendrimers for theranostic applications in oncology Thomas et al. [22] described the preparation of G5 PA-MAM dendrimers conjugated to fluorescein isothiocyanate for imaging and recombinant fibroblast growth factor-1 (FGFR), which is overexpressed in a wide variety of tumors, for tumor targeting purposes (Fig. 3) . Confocal microscopy and flow cytometry showed the specific binding and the internalization of the G5 FGFRdendrimer conjugate. The binding of the conjugated nanoparticles showed modest binding in the breast cancer cell line MCF7, which is FGFR-negative in unstimulated MCF7 cells, and significant specific activity against the PC3 prostate cancer and MCR endothelial cell lines.
The same authors reported the synthesis and in vitro evaluation of a G5 PAMAM-folate receptor (FR)-targeted nanoconjugate that releases the anticancer drug doxorubicin (DOX) via a photochemical mechanism (Fig. 4 ) [23] . Doxorubicin is loaded onto the surface of the dendrimer through the UV photocleavable ortho-nitrobenzyl group linker at 365 nm.
Another study described by Singh et al. [24] highlighted the site-specific enhanced image contrast and drug loca- conjugate. These dendritic conjugates were evaluated for their anti-cancer drug delivery and tumor growth efficiency using loaded 5-fluorouracil (~31%) against cervical KB tumor cells in mice. Interestingly, the folate−PEG −dendrimer conjugate was safe and effective in tumor targeting compared with a non-PEGylated formulation.
Another example of the development of FA-PEG-G3.5 PAMAM conjugates onto quantum dots (QDs) in HeLa tumor cells has been described by Zhao et al. [25] . Significant cellular uptake was observed based on in vivo imaging experiments.
Recently, Li and coworkers [26] described the preparation and development of PEGylated supramolecular nanoplatforms based on lipoic acid-functionalized amphiphilic dendrons for efficient platinum(II)-based drug delivery and near-infrared (NIR) absorption tracking using Cy5.5 as NIR fluorescence probes named TSPDS (Fig. 5) . Interestingly, the rapid disintegration of this supramolecular dendritic system occurred by a pH/redox dual-responsive process based on the specific tumor intracellular environment: low pH value and high glutathione concentration. The redox-cleavable disulfide linkages and the release of platinum(II) drug by the acidlabile bonds around the metal occurred in the nuclei exerting antitumor activity, which was comparable to cisplatin in the A549 lung solid tumor cell line. In vivo, this supramolecular platform showed efficient therapeutic efficacy against nude mice with A549 xenografts following intravenous injection. In vitro and in vivo NIR fluorescence imaging, also in nude mice with A549 tumor xenografts, showed the intracellular platinum delivery of the nanodevice. The pharmacokinetic profile showed that the maximum plasma concentration (C max ) of Pt(II) from the PEGylated nanodevice was approximately eight-fold higher than cisplatin alone. In addition, higher accumulation in tumor tissue compared with cisplatin has been noted, minimizing nephrotoxicity and enhancing the antitumor effects. The area under the curve (AUC), the half-life (t 1/2 ), and the blood clearance profiles of the nanodevice were improved compared with cisplatin, with a 22-fold increase, three-fold increase, and 20-fold decrease, respectively. Importantly, based on cellular morphological analysis, strongly reduced renal toxicity (cell deformation in renal tissue) of platinum-based drugs has been observed compared with cisplatin. No lesions as well as no abnormalities in other major organs, such as the heart, liver, spleen, and lung, were observed in mice.
These non-exhaustive examples (vide supra) highlight the potential role of dendrimers in the theranostic field.
Magnetic resonance imaging
An interesting analysis of dendrimers as versatile MRI agents has been recently published by McMahon et al. [14] . Paramagnetic Gd(III) [27] and Mn(II) dendrimers [28] , as well as the use of superparamagnetic iron-oxide nanoparticles, which allow the formation of superparamagnetic dendrimers (also named magnetodendrimers), have been prepared. Thus, the stabilization of maghemite nanoparticles by G4.5 PAMAM dendrimers allows the use of these nanoparticles in MRI cell tracking studies [29, 30] . Additional dendrimer-MRI contrast agents include chemical exchange saturation transfer (CEST), diamagnetic CEST, paramagnetic CEST [31, 32] , and fluorinated dendrimers [33] .
Gadolinium (Gd(III)) has seven unpaired electrons, and this paramagnetic nanodevice displays the highest relaxivity related to the nuclear magnetic resonance frequency, whereas manganese (Mn(II)) shows anomalous relaxation behavior, and at higher fields, exhibits relaxation that is higher than gadolinium [14] .
MRI contrast agents currently approved for clinical applications are mostly low-molecular weight Gd(III) chelates, such as Gd-diethylenetriaminepentaacetic acid (DTPA) and Gd-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), but these imaging agents rapidly extravasate from blood circulation and are eliminated via renal filtration (Fig. 6 ). Consequently, a transient time window for contrast-enhanced MRI examinations and limited efficacy in improving MRI quality were observed. Consequently, macromolecular Gd(III) complexes show prolonged blood circulation and preferential accumulation in solid tumors due to the hyperpermeability of tumor vasculature [34] . The addition of Gd(III) to create dendrimer-based MRI contrast agents has been described by several groups. The first study to validate the feasibility of using dendrimers chelated with metals ions as MRI contrast agents was published by Wiener et al. [27] and showed the applicability of G2 and G6 PAMAM dendrimers as MRI contrast agents [28] . The surface of PAMAM dendrimers was functionalized with DTPA to complex Gd(III) as an imaging agent. In total, 11 and 170 chelate groups were grafted on the surface of G2 and G6, respectively (Fig. 7) . These Gd(III)-macromolecules enhanced conventional MRI in mice. The generation 6 dendrimer displayed a prolonged enhancement compared with G2 and Gd(III)-DTPA. The enhancement half-lives were 200, 40, and 24 min for G6, G2, and Gd(III)-DTPA, respectively. In addition, the G6 dendrimer overcame the saturation effects associated with the three-dimensional time of flight MRI angiography associated with a long longitudinal relaxation time of the blood. Other biodegradable dendrimer-based MRI contrast agents (Gd(III)-DTPA) are as follows: 1) PEG-conjugated ester-amide dendrimer [35] ; 2) G0-3 polyester (PE) dendrimers [36] ; 3) G2 FA-PEGconjugated PE dendrimer [37] ; and 4) G1-G4 PEG-conjugated PE dendrimer [38] .
The G4 PAMAM dendrimer has been synthesized and developed for use as a target-specific MRI contrast agent by Konda et al. [39] with Gd(III)-DTPA chelates and FA units to target upregulated FRs in more than 80% of ovarian tumors. In vitro, mouse erythroleukemia cells expressing FRs bind the radiolabeled folate-dendrimer chelate, resulting in a greater than 2700% increase in binding compared with untreated cells. In vivo, this macrocycle showed significant contrast enhancement (33%) in ovarian tumor xenografts in mice compared with a non-specific agent without FA. These studies suggest that dendrimeric MRI agents with high molecular relaxivities (1,646 mmol
) can be used to specifically target FRs on tumor cells and ovarian tumors. . . . . . . . . . . . . . . . . . . . . . . . . . SCIENCE CHINA Materials   1372 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . It is known that macromolecular Gd(III) chelates are efficient as MRI contrast agents for blood pool and tumor imaging [40] . The main drawback of this system is their limitation in clinical development, such as safety concerns related to slow excretion and long-term gadolinium uptake in tissues. To solve these issues, Xu et al. [34] prepared G6 PAMAM conjugated with Gd(III) DO3A chelate [G6 PAMAM-(Gd-DO3A)] and cleavable disulfide spacer [G6-PAMAM-cystamine-(Gd-DO3A)] dendrimers as biodegradable macromolecular MRI contrast agents (Fig. 8) . This G6 PAMAM dendrimer showed rapid blood clearance and lower liver uptake in nude mice compared with a non-degradable G6 PAMAM-Gd(III) dendrimer without cleavable cystamine linker following intravenous injection. Dynamic MRI showed that the Gd (III) chelate was excreted via renal filtration and accumulated in the urinary bladder. The T1 and T2 relaxivities of the G6-PAMAM-Gd(III)-cystamine dendrimer were 11.6 and 13.3 mmol −1 L s −1 , respectively. The G6-PA-MAM-Gd(III)-cystamine dendrimer was effective for contrast-enhanced blood pool imaging for approximately 5 min, and tumor imaging in female nude mice bearing MDA-MB-231 human breast carcinoma xenografts. However, the G6-PAMAM-Gd(III)-cystamine dendrimer displayed high toxicity in mice, likely due to the hemotoxicity related to the inherent toxicity of the PAMAM dendrimer structure.
Several other examples in which Gd(III)-DOTA was covalently grafted onto the dendrimer backbone for molecular imaging purposes, such as MRI angiography and tumor angiogenesis imaging, include: poly-L-lysine octasilsesquioxane dendrimers developed by Kaneshiro et al. [41] and PEG-backbone core dendrimeric nanoparticles bearing Gd-DOTA chelate clusters as dynamic MRI contrast agents developed by Cyran et al. [42] . As shown in Fig. 9 , Cyran et al. [42] prepared three different contrast agents based on PEG-core and (Gd-DOTA)-conjugated units: PEG12000-Gen3-(Gd-DOTA), PEG12000-Gen4-(Gd-DOTA), and PEG20000-Gen4-(Gd-DOTA). These polymeric MRI contrast agents displayed T1 relaxivity per Gd ion of 9.0, 9.9 and 9.8 mmol −1 L s −1 , respectively, and blood half-life of 25, 49 and 72 min, respectively. These macromolecular systems have been used in quantitative assays of endothelial leakiness and tissue vascular tissue density to differentiate cancer and normal cells in a model of human breast cancer (MDA-MB-435) in mice. PEG20000-Gen4-(Gd-DOTA) showed high breast tumor penetration and low trans-endothelial residence in normal soft tissue microvessels. PEG20000-Gen4-(Gd-DOTA) displayed good differentiation of cancers from normal muscle. PEG12000-Gen4-(Gd-DOTA) and PEG12000-Gen3-(Gd-DOTA) both showed penetration in a breast tumor and normal muscle.
Recently, the first in vivo MRI study on the theranostic potential of dendrimersomes (amphiphilic Janus-dendrimers as a relevant alternative to liposomes), which are able to self-assemble into nanosized vesicles, was de- . . . . . . . . . . . . . . . . . . . . . . . . . . . . scribed by Filippi et al. [43] . As shown in Fig. 10 , this Janus construction is based on the 3,5-C 12 -EG-(OH) 4 dendrimer co-loaded with the glucocorticoid anticancer agent prednisolone phosphate, which is encapsulated in the inner core of the dendrimersome, and the amphiphilic MRI agent Gd(III)DOTAGA(C 18 ) 2 , which is incorporated in the dendrimersome bilayer. In cell viability assays, this dendrimersome displayed no toxicity against murine fibroblast cell line (NIH/3T3) indicating no toxicity associated with the presence of the vehicle. Strong cytotoxicity was observed against HUVEC cell lines and moderate against melanoma B16-F10 tumor cells after incubation times of 6 and 24 h. This nanovesicle showed high longitudinal relaxivity and consistent contrast enhancement in a xenograft B16F10 melanoma tumor in mice. Intratumoral distribution appeared inhomogeneous, likely due to local differences in the vascularization. Dendrimersome biodistribution studies showed a high concentration in the liver, spleen, and tumor compared with other organs such as the kidney, lung, muscle and heart.
Criscione et al. [44] developed noninvasive perfluorinated G3 and G6 PAMAM-dendrimers as in vivo molecular imaging agents using the 19 F magnetic resonance imaging system, which is centered on the CF 3 resonance principle. The covalent attachment of perfluoroalkyl substituents (-NHCOCF 2 -CF 2 -CF 3 ) to the surface of G3 PAMAM dendrimers mediated self-assembly (specific formation) into a complex system with unique and adjustable physiochemical properties related to the pH of the external environment (pH 2, 7 and 12). Electrostatic repulsive forces were responsible for driving particulate disassembly of the perfluorinated G3 PA-MAM-dendrimers. pH-dependent T1 relaxation times (298.3, 410.7, and 428.8 ms at pH 7, 5, and 2, respectively) were observed by 19 F magnetic spectroscopy, showing a stable and rigid network at approximately pH 7, but was disrupted at pH 2. This disassembly occurred over time and could allow a potential control of the release of encapsulated agents. Then, a generation 6 fluorinated dendrimer was prepared and PEG chains were grafted on its surface to enhance its circulation and transport properties in the blood. This PEGylated nanoparticles have been used in in vivo experiments, and was injected intravenously into the female B6 mouse systemic circulation. 19 F and 1 H images showed the presence of the PEGylated nanoparticles in the mouse kidney vasculature.
Recently, Luong et al. [45] highlighted the synthesis and development of polyvalent theranostic nanocarriers. The construction of this nanoparticle is based on the superparamagnetic iron oxide nanoparticle core (Fe 3 O 4 ) decorated with a FA-G4 PAMAM dendrimer surface that encapsulates the highly potent hydrophobic anticancer agent 3,4-difluorobenzylidene-curcumin. The 3-aminopropyl trimethoxysilane chain links the FA-dendrimer and the Fe 3 O 4 particle (Fig. 11) . Compared with nontargeted nanoparticles, the targeted nanoparticles exhibited an improved ability to enhance MRI contrast and faster cellular uptake in both SKOV3 ovarian and HeLa cervical cancer cells. These tumor cells overexpress FA receptors on the tumor surface. In addition, the targeted nanoparticles resulted in a higher percentage of apoptotic and necrotic cells with the ability to upregulate phosphatase and tensin homologue deleted on chromosome ten (PTEN) and caspase-3, and downregulate nuclear factor-κB (NF-κB). This anticancer profile could help to overcome anticancer drug resistance and the recurrence of cancer after initial treatment. REVIEWS . . . . . . . . . . . . . . . . . . . . . . . . . . SCIENCE CHINA Materials   1374 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Gamma scintigraphy
Almutairi et al. [46] have developed a biodegradable and noninvasive 76 Br (radiohalogen moiety)-labeled positronemitting dendritic nanoprobe targeting α v β 3 integrin receptors in an angiogenic mouse model. As shown in Fig.  12 , the architecture of this PET dendritic nanoprobe is based on a modular multivalent core-shell scaffold consisting of a biodegradable heterofunctional dendritic core functionalized with heterobifunctional polyethylene oxide (PEO) chains to protect the shell. The PEO chains dictate PKs and maintain the biological activity. In addition, the radioactive moieties have been introduced in several branches of the dendritic core to prevent in vivo dehalogenation, whereas cyclic arginine-glycine-aspartic acid (RDG) moieties were introduced at the terminal ends of the PEO chains, enhancing their accessibility to α v β 3 integrin receptors. This targeted nanoprobe displayed a 50-fold enhanced binding affinity to α v β 3 SCIENCE CHINA Materials. . . . . . . . . . . . . . . . . . . . . . . . . . . . model of rat angiogenesis with intravenous administration, high specific accumulation of the 76Br-labeled dendritic nanoprobe targeting α v β 3 -integrins was observed in angiogenic muscles, whereas the excretion profile showed fast urinary elimination of the non-targeted dendritic nanoprobe compared with the RGD-nanoprobe, also eliminated via the stomach and feces.
Similarly, Dijkgraaf et al. [47] synthesized DOTAconjugated multivalent cyclic-RGD dendrimers specifically targeting α v β 3 integrins in in vitro and in vivo (nude mice) models of SK-RC-52 tumors. The In-labeled RGD-dendrimers showed specific enhanced uptake in α v β 3 integrin-expressing tumors in vivo.
Kobayashi et al. [48] described the synthesis and development of the G4-PAMAM dendrimer (64 surface amines), which was conjugated with 43 molecules of 2-(pisothiocyanatobenzyl)-6-methyl-diethylene triamine penta-acetic acid (1B4M) and the murine monoclonal IgG1 (OST7) followed by the conjugation of 111 In or 153 Gd as labeling moieties to generate 111 In-OST7-G4-(1B4M) 43 and 153 Gd-OST7-G4-(1B4M)43 nanoparticles, respectively. The immunoreactivity, biodistribution, and tumor targeting of these two G4-PAMAM dendrimer derivatives were evaluated in mice. The maximum specific activity of 111 In-OST7-G4-(1B4M) 43 and 111 In-OST7-1B4M was 12,700 and 263 mCi mg , respectively. The binding efficiency to human osteosarcoma cells (KT005), which express the antigen of OST7 using OST7-G4-(1B4M)43 and OST7-1B4M was 91 and 84%, respectively. Biodistribution studies in mice showed that 111 In-OST7-G4-(1B4M) 43 and 153 Gd-OST7-G4-(1B4M)43 were cleared faster from the blood and accumulated in the liver faster compared with 111 In-OST7-1B4M and 153
Gd-OST7-1B4M. 153 Gd-OST7-G4-(1B4M)43 displayed specific accumulation in the KT005 tumor site.
The same team evaluated the in vivo biodistribution of the G2-PAMAM dendrimer (16 surface amine groups) conjugated with 1B4M and humanized anti-Tac IgG (HuTac) to generate the G2-PAMAM-IB4M-HuTac dendrimer, which was then radiolabeled with 111 In and 88 In-G2-PAMAM-IB4M-HuTac and 88 Y-G2-PAMAM-IB4M-HuTac accumulated in the liver, kidney, spleen, and bone in nude mice following intravenous administration. Radiolabeled G2-PAMAM-1B4M-HuTac dendritic nanoprobes showed faster blood clearance and greater liver and spleen accumulation compared with native HuTac.
Li and coworkers [50] developed the 188 Re-labeled hyperbranched polysulfonamine-based dendrimers (HPSA), named CH12-HSPA- 188 Re, as a robust tool for targeted cancer diagnosis and radiotherapy system to perform SPECT imaging studies (Fig. 13) . HPSA is an interesting biomaterial due to its strong intracellular permeability. Two terminal amine groups were grafted onto the surface of HPSA: N-hydroxysuccinimidyl S-acetylmercaptoacetyl triglycinate (NHS-MAG3) for labeling 188 Re, which is a versatile radioactive nuclide for both nuclear and radioimmunotherapy, and N-(k-maleimidoundecanoic acid) hydrazide for tethering the human-mouse chimeric monoclonal antibody CH12, which selectively recognizes epidermal growth factor receptor vIII (EGFRvIII). EGFR is a cell-surface receptor overexpressed in the neovascu- REVIEWS . . . . . . . . . . . . . . . . . . . . . . . . . . SCIENCE CHINA Materials   1376 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Re-CH12-HSPA was prolonged compared with free 188 Re following tail vein injection. Based on the same in vivo experiment, the level of tumor radioactivity increased with time, while those of the kidney and blood were gradually decreased.
In a recent study, Shi and coworkers [51] used amineterminated G5 PAMAM dendrimers (G5·NH 2 ) as a platform to sequentially modify with 3-(4ʹ-hydroxyphenyl) propionic acid-OSu (HPAO) and FA linked with PEG, followed by acetylation modification of the dendrimer remaining surface amines and labeling of radioactive iodine-131 ( 131 I). Their data show that prior to 131 I labeling, the generated G5·NHAc-HPAO-PEG-FA dendrimers conjugated with approximately 9.4 HPAO moieties per dendrimer are noncytotoxic at a concentration up to 20 μmol L −1 , and can target cancer cells overexpressing FA receptors (FAR) due to the modified FA ligands. In the presence of the HPAO phenol group, radioactive 131 I is able to be efficiently labeled onto the dendrimer platform with good stability and high radiochemical purity. The developed dendrimeric nanoplatform enables targeted SPECT imaging and radiotherapy of a FAR-overexpressing xenografted tumor model in vivo.
In another study reported by Shi and coworkers [52] , the G5 PAMAM dendrimers were sequentially linked with PEG, targeting agent chlorotoxin (CTX), and HPAO. This was followed by acetylation of the remaining dendrimer terminal amines and radiolabeling with 131 I to form the targeted theranostic dendrimeric nanoplatform. Results reveal that the dendrimer platform possessing 7.7 CTX and 21.1 HPAO moieties on each dendrimer displays excellent cytocompatibility in a given concentration range (0−20 μmol L −1 ) and can specifically target cancer cells overexpressing matrix metallopeptidase 2 (MMP2) due to the attached CTX. With the good stability and high radiochemical purity of the labeling of radioactive 131 I, the dendrimer platform is able to be used for targeted SPECT imaging and radiotherapy of an MMP2-overexpressing glioma model in vivo.
Grünwald et al. [53] developed G5 PAMAM dendrimer-coated adenovirus (Ad5-CMV/NIS) encoding sodium iodide symporter as a theranostic gene nanoplatform using the 123 I scintigraphy technique. The authors of this study highlighted the efficient therapeutic potential for systemic radiovirotherapy in a HUH7 liver cancer xenograft mouse model (Fig. 14) . Importantly, the DMAA-IPA nanoparticles were specifically designed to improve solubility by introducing positive charges (ammonium salts), which did not affect the stability of the link between the DMAA-IPA and the dendrimer. These nanoparticles has an average molecular weight of 37,000 g mol
, a hydrodynamic radius of 2.4 nm, and an iodine content of~33%. G4-PAMAM (DMAA-IPA) 37 represents a first-in-class dendritic nanoparticle for CT imaging due to its high iodine loading capacity. 177 Lu-G4-PAMAM dendrimer-folate-bombesin with gold nanoparticles in dendritic cavities has been synthesized by Mendoza-Nava et al. (Fig. 15) [55] . This nanoparticle, named 177 Lu-DenAuNP-folate-bombesin, represents a potential theranostic radiopharmaceutical agent. Bombesin, a 14-amino acid peptide, and bombesin receptors, have been demonstrated to play a role in cancer. Gastrin-releasing peptide receptor is a bombesin receptor subtype frequently expressed in tumors. Binding studies in the T47D breast tumor cell line, which overexpresses FRs and gastrin-releasing peptide receptors, showed specific cell uptake of these nanoparticles. After intratumoral administration, high retention in T47D-induced tumors in mice was observed, and 177 Lu-G4-PA-MAM dendrimer-folate-bombesin remained in the T47D tumor up to 96 h.
Due to the higher X-ray attenuation coefficient of Au nanoparticles than that of iodine for iodine-based CT contrast agents (e.g., Omnipaque), Au nanoparticles have Figure 14 Schematic chemical structure of G4-PAMAM (DMAA-IPA) 37 . Materials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
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November 2018 | Vol. 61 No . 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1377 been entrapped within dendrimers for various CT imaging applications [56] [57] [58] . In order to reduce the dendrimer terminal amine-induced cytotoxicity, the dendrimer terminal amines can be acetylated, and the acetylated dendrimer-entrapped gold nanoparticles (AuDENPs) can be used for blood pool [59] and tumor [60] CT imaging.
In a typical work, Wang and coworkers [60] from Shi's team reported the development of acetylated G5 PAMAM Au-DENPs for in vitro and in vivo CT imaging of cancer cells. These nanoparticles have been used for both in vitro and in vivo CT imaging of a SPC-A1 human lung adenocarcinoma cell line. Micro-CT images showed that SPC-A1 cells could be detected under X-ray after incubation in vitro, showing that the nanoparticles were uptaken in the lysosomes of SPC-A1 cells. In a mouse xenograft tumor model, after both intratumoral and intraperitoneal administration of the nanoparticles, high image resolution was observed. Interestingly, based on flow cytometric analysis of the cell cycle, no changes in cell morphology, viability, or the cell cycle were observed, indicating the biocompatibility of Au-DENPs nanoparticles.
In another study, Shi et al. [61] developed acetylated FA-G5 PAMAM dendrimer-entrapped gold nanoparticles that were suitable for in vitro and in vivo CT imaging of cancer cells, such as the human lung adenocarcinoma cell line (SPC-A1 cells; Fig. 16 ). Fifty Au per NAc-G5 PAMAM dendrimers and five FA units per dendrimer have been conjugated (named 50Au-5FA-G5 PAMAM). Gold nanoparticles have been used as probes in optical molecular imaging for cancer detection and treatment due to their surface plasmon absorption and light-scattering properties [62, 63] . In addition, gold offers several advantages over conventional iodine-based agents, such as higher X-ray absorption coefficient and no specific toxicity, as well as tunable surface modifications for introduction of the targeting ligand [64] Micro-CT images have shown that SPC-A1 cells could be detected under X-ray after incubation with this acetylated Au-PAMAM dendrimer in vitro and in vivo. Thus, xenograft tumors in mice can be imaged after both intratumoral and intraperitoneal administration of these nanoparticles. The uptake process of this nanomaterial in SPC-A1 cells occurs in lysosomes, and has been demonstrated using transmission electron microscopy. After tumor cell incubation, no cell damage (e.g., morphology changes), as well as no changes in the cell cycle were demonstrated, indicating their low toxicity and good REVIEWS . . . . . . . . . . . . . . . . . . . . . . . . . . SCIENCE CHINA Materials   1378 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . biocompatibility. In order to achieve higher loading of Au nanoparticles within the dendrimers, the dendrimer periphery can be modified with PEG [65] . Further, through the PEGylation chemistry, targeting ligands of folate [66] or lactobionic acid [67] can be linked onto the surface of Au-DENPs through the PEG spacer for targeted CT imaging of FRexpressing KB tumor and human hepatocellular carcinoma tumor, respectively. To avoid the use of expensive high generation PAMAM dendrimers, low-generation dendrimers (e.g., G2) can also be modified with PEG for effective entrapment of Au nanoparticles with a size of 1-2 nm for tumor CT imaging applications [68, 69] . Alternatively, dendrimer-stabilized Au nanoparticles (Au DSNPs) can be prepared using G2 PAMAM dendrimers as a stabilizer under a hydrothermal condition without additional reducing agents for animal organ [70] and tumor [71] CT imaging.
To further improve the CT imaging sensitivity, AuDENPs can be combined with diatrizoic acid (DTA), which is an iodine-based small molecular CT contrast agents. The Au-DENPs can be modified with DTA via EDC/NHS chemistry after the formation of Au nanoparticles to improve the CT imaging sensitivity due to the co-existence of two types of radiodense elements of Au and I [72] . Alternatively, DTA-modified G5 PAMAM dendrimers can be used as a template to synthesize AuDENPs. After the acetylation of dendrimer surface amines, Au DSNPs can be formed. The formed functional Au DSNPs can be used for enhanced blood pool CT imaging due to the presence of both elements of Au and I [73] .
Optical imaging
Backer et al. [74] synthesized and developed vascular endothelial growth factor (VEGF)-BD/Cy5 nanoparticles for NIR tumor vasculature imaging (Fig. 17) . Boronated G5-PAMAM dendrimers (128 surface amino groups) were conjugated with 1) 1,050-1,100 decaborate-boron atom systems per dendrimer for NIR imaging and potential boron neutron capture therapy, 2) VEGF (4:1 molar ratio) to target tumor neovasculature, and 3) near-IR Cy5 dye allowing near-IR fluorescent imaging both in vitro and in vivo. This boronated dendrimer displayed no cytotoxicity against HEK293 cells expressing VEGFR-2. Based on NIR imaging studies, selective accumulation in 4T1 mouse breast carcinoma was observed, mainly at the tumor periphery where angiogenesis was most active. Interestingly, this accumulation decreased in mice pretreated with VEGF-fusion toxin specifically killing VEGFR2-over expressing endothelial cells.
Tsien et al. [75] prepared dendrimers functionalized with fluorescently-labeled activatable cell-penetrating peptides, which are activated upon exposure to proteases characteristic of tumor tissues. These dendrimers were used to visually delineate the margin between tumor and adjacent tissues, during the resection surgery of mammary adenocarcinoma tumors in transgenic mice. These mice had better long-term tumor-free survival and overall survival than those treated by classical surgery without the help of the dendrimer.
Taratula et al. [76] described the preparation of G5 polypropylenimine (PPI) dendrimer-encapsulated silicon naphthalocyanine (SiNc) as a nanoplatform for NIR fluorescence imaging and combinatorial anticancer phototherapy with dual photodynamic (PDT) and photothermal (PTT) therapeutic mechanisms. Encapsulation of SiNc occurs in the hydrophobic cavity of PPI dendrimers providing its aqueous solubility and its NIR fluorescence, PDT and PTT imaging properties. This construction showed high photostability of SiNc, and under NIR irradiation manifested robust heat generation capability (ΔT = 40°C), producing reactive oxygen species (ROS) for PDT and PTT anticancer therapy. In addition, no SiNc release has been observed. Interestingly, by regulating the laser power density, the therapeutic mechanism of the SiNc-nanoprobe could be switched from PDT to combinatory PDT-PTT treatment. Importantly, in vivo, the SiNc-nanoprobe combined with NIR irradiation in nude mice completely eradicated A2780/AD resistant ovarian cancer cells transplanted into the animal.
The same team highlighted the synthesis and development, for PDT, of a multifunctional theranostic platform using silicon-based phtalocyanine moieties (imaging agents), which are encapsulated into G4 PPI dendrimers named PEG-G4 PPI-LHRH-PcSi(OH)(mob) (Fig. 18 ) [77] . Phthalocyanines (Pc) have outstanding NIR optical . . . . . . . . . . . . . . . . . . . . . . . . . . . . properties and fluorescence emission but suffer in their tendency to form aggregates through π-π staking and hydrophobic interactions in an aqueous medium. The theranostic properties of this platform are completed by the production of toxic ROS upon exposure to light to tackle tumor cells. To improve the biocompatibility of this nanoparticle, its surface has been modified with PEG chains. In addition, luteinising hormone-releasing hormone (LHRH) protein was also grafted on the PPI surface through the PEG chains for tumor cell selectivity. The use of both PEG chains and LHRH peptide decreased the cytotoxicity of this platform and enhanced internalization into cancer cells. Low dark cytotoxicity (cell viability), and strong phototherapeutic effects due to high production of intracellular ROS were observed in LHRH receptor-positive A280/AD multidrug-resistant human ovarian carcinoma cells compared with LHRH receptornegative SKOV-3 human ovarian carcinoma cell lines. No substantial difference was observed between cellular internalization of LHRH-targeted and non-targeted particles into LHRH-negative cancer cells. In vivo intravenous administration of tumor-LHRH targeted nanoparticles in mice bearing human ovarian carcinoma xenografts induced good fluorescent images in different organs, such as the tumor and liver, compared with the spleen, kidney, heart, and lung, indicating effective tumor targeting capability of the nanoparticles.
Cytochrome c is an essential mediator of apoptosis when released from the mitochondria to the cytoplasm, e. g., in response to DNA damage, and is observed in many cancer cells including cancer stem cells. Interestingly, the delivery of cytochrome c directly into the cytoplasm of cancer cells selectively initiates apoptosis in many cancer cells [78] .
Santra et al. [79] synthesized a water-soluble hyperbranched polyhydroxyl dendrimer for theranostic properties. These nanoparticles carried hydrophilic protein cytochrome c as a cellular apoptotic initiator, dialkylcarbocyanine dye, which is an NIR amphiphilic fluorescent dye, and FA as targeting moieties to target FR-positive cancer cells. The human lung carcinoma cell line A549 (FR-positive) and the breast carcinoma cell line MCF7 (FR-negative) were selected for this study. The intracellular release of cytochrome c and apoptosis were observed with confocal microscopy. These folate-conjugated nanoparticles induced apoptosis in FR-positive lung carcinoma cells (A549), but not in MCF7 tumor cell lines (FR-negative), suggesting the specificity of the nanoparticles' cytotoxic potency.
Interestingly, dendrimers were also used as coating layers to encapsulate inorganic nanoparticles for molecular imaging. Thus, Zhao and coworkers [25] developed folate-PEG-3.5-PAMAM dendrimers encapsulating luminescent CdSe/ZnS QDs as an imaging agent for selective targeting of FR-positive tumor cells. In this construction, 3.5 PAMAM dendrimers were used to encapsulate QDs. Based on in vivo experiments, the cellular uptake in HeLa tumor cells is more significant with folate-PEG-PAMAM dendrimers-QDs compared with nonfolate PAMAM dendrimer-QD systems. Folate-PEG-PAMAM dendrimer-QDs are initially bound to tumor cell surfaces through FRs, followed by slow endosomal escape and release into tumor cells. Phosphorus-containing dendrimers, synthesized in the group of Caminade and Majoral [80] , have been functionalized with both fluorescent groups and bioactive terminal functions. The first generation phosphorhydrazone dendrimer functionalized by 12 azabisphosphonate groups is able to trigger the human immune system, and can induce the multiplication by several hundreds of the number of Natural Killer (NK) cells. NK cells are particularly important, as they are able to fight against various infection and numerous leukemia and carcinoma [81] . As shown by Poupot et al. [82] a fluorescently labeled analogue dendrimer (Fig. 19 ) was used to decipher the biological processes leading to the anticancer properties. It was shown that the first step is the anti-inflammatory activation of monocytes, which is particularly important against chronic inflammatory diseases [83, 84] . In second time, a cross-talk between monocytes and NK cells induces the proliferation of the latter, including with blood from patients suffering of multiple myeloma disease [85] .
Recently Mignani, Cresteil and Majoral et al. [86] de- scribed first-in-class phosphorhydrazone dendrimers which were capped with pyridine imine terminal functions (free or complexing Cu(II)) showing good anticancer properties against a number of cancerous cell lines. The third generation was shown the most potent derivatives, with IC 50s values ranging 0.3-1.6 μmol. Interestingly, the copper complexes were found more toxic toward cancerous cell lines a, but less toxic towards noncancer cell lines, than the free ligands. To get insight into their mode of action, a fluorescent analogue has been synthesized, in which the fluorophore are inside the structure (Fig. 20) . It was shown that the free dendrimer and the corresponding copper complex behave differently inside the cells. The free dendrimer moderately activates caspase-3, whereas the complex strikingly reduces the caspase-3 activity, and induces a noticeable translocation of Bax to the mitochondria, resulting in a severe DNA fragmentation. This is an original pathway for inducing apoptosis of cancer cells [87] . 
CONCLUSIONS AND PERSPECTIVES
Nanoparticles such as dendrimers are significantly impacting the development of theranostic applications, which can be considered as the cement between diagnosis and treatment. Among the different nanoparticles used in theranostics, biodegradable and biocompatible dendrimers represent an attractive platform based on their high level of structural control, and potential for chemical functionalization.
Using dendrimers, a panel of diverse imaging modalities allowing diverse strategies to treat and visualize tumors can be developed: MRI, PET, SPECT, CT, and optical imaging. Recent approaches in theranostics using dendrimers were summarized in this review for biome- Figure 19 Fluorescently-labeled first generation phosphorhydrazone dendrimer able to trigger the human immune system towards either anti-inflammatory properties or anti-cancer properties. dical applications in oncology. These strategies will help improve disease management. Table 3 notes the imaging agents used with dendrimers.
Using dendrimers as theranostic agents, several issues can be addressed, such as toxicity and biocompatibility, including long circulation time and clearance rate, as well as biodegradability and purification. In general, bench-tobedside translation of nanoparticles and dendrimers in particular, remains an important challenge. Indeed, to date, few dendrimers are in the clinical phase for systemic administration (vide supra), despite the fact that dendrimers are the focus of a large number of research publications, with approximately 2500 between 2006 and 2013 [90, 91] . In addition, specifically regarding the use of dendrimers as MRI agents, McMahon and Bulte [14] have highlighted that over the last two decades, there has been an explosion of studies in MRI theranostics with over 400 papers published and 2800 citations a year (2013-2016).
The challenge is how to jump the 'valley of death' between academic researches based on an idea, general knowledge, basic research, and development processes and the clinical applications developed in pharmaceutical industries. Recently, several of us (Mignani, Shi, Rodrigues, Tomas and Majoral) have proposed a simple guideline to scientists (chemists, biologists, pharmacologists, engineers, and physicians) working in the dendrimer field based on several translational requirements to move towards an Investigational New Drug application (IND), which is an evaluation of the safety profile before initiating clinical trials [92] . In addition, Mignani and Majoral have defined the term dendrimer space concept as an approach that affords a new paradigm of thought for medicinal chemists and opens new and promising avenues for the identification of original and biocompatible dendrimers and dendrimer-based drugs [93] , which have been analyzed by Leiro et al. [94] regarding the future of degradable dendrimers in theranostics.
Within the dendrimer field, in 2012, Starpharma Holding Limited (Melbourne, Australia) started two pivotal Phase III trials for the treatment of bacterial vaginosis with VivaGel® (SPL7013). In addition, Starpharma has now received FDA Phase III approval. Starpharma/ AstraZeneca has recently advanced from Phase I to Phase II with poly(lysine)dendrimer based nanocarrier encapsulating docetaxel (DEP® docetaxel) showing superior anticancer activities against several important solid cancer types including breast, prostate, lung and ovarian tumors. Importantly, patients treated with DEP®docetaxel had no neutropenia side effects, and lifethreatening toxicity seen in patients treated with conventional docetaxel formulations opening new opportunities to develop new anticancer agents in particular [8, 9] , and new therapeutic strategies in general.
Finally, the development of theranostic approach in other therapeutic domain such as HIV [95] and inflammation [96] should be possible. For instance, in the inflammation domain, the theranostic approach can be used to facilitate the evaluation of macrophage uptake and the biodistribution of the drug carrier [96] . 
